Oncology

Latest News

The thinking around which patients are eligible for liver transplants needs to evolve, the authors noted, as the criteria used to evaluate fitness for transplant were proposed nearly three decades ago. | Image credit: Peakstock - stock.adobe.com

New Developments Warrant Rethinking HCC Transplant Criteria

By Jared Kaltwasser

April 29th 2025

Downstaging and bridging strategies are changing how hepatocellular carcinoma (HCC) is treated.

Women with fatigue | Image credit: Adobe Stock

Fatigue, Depression Hit Harder on Women Cancer Survivors, Data Show

By Mary Caffrey

April 29th 2025

senior scientist | Image credit: Ohio State University

Proving the Concept: A Sampler of Early-Stage Science at AACR 2025

By Mary Caffrey

April 28th 2025

NSCLC | Image: Lung Cancer Foundation of America

Zongertinib Shows Durable Responses With No Interstitial Lung Disease in HER2-Mutated Advanced NSCLC

By Mary Caffrey
Brooke McCormick

April 28th 2025

Considering the life-threatening risk of TLS, the researchers underscored the importance of identifying patients at particular risk of the complication. | Image credit: mi_viri - stock.adobe.com

Optimized Strategies Needed for TLS Prevention, Intervention in SCLC

By AJMC Contributor

April 23rd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

November 1st 2014

CTFPHC: Do Not Use PSA to Screen for Prostate Cancer

The guideline, published in the Canadian Medical Association Journal, recommends against using PSA to screen for prostate cancer, pointing to the high risk of false positives and overdiagnosis.

October 31st 2014

Computer-Aided Mammograms Increase Medicare Cost-Burden: JAMA Study

The retrospective study analyzed SEER data from 2001 through 2009, and found that the annual CAD prevalence among Medicare screening mammograms increased from 3.5% to 79.7%.

October 31st 2014

Diagnostic Lung Biopsies a Big Drain on Medicare, Study Finds

The retrospective study, results of which were presented at the 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology, showed that the total diagnostic workup cost for the study sample of Medicare beneficiaries was $38.3 million.

October 30th 2014

Mental Health Issues Overshadow Breast Cancer Survivorship

The Danish study, published in the Journal of Clinical Oncology, identified a 70% greater risk of severe depression in the first year after diagnosis.

October 30th 2014

After Pembrolizumab, Promising Results With Nivolumab in NSCLC

Phase 2 results from the Checkmate-063 trial found that treatment with the PD-1 inhibitor Nivolumab (Opdivo) resulted in a median OS of 8.2 months in NSCLC patients who had received 2 prior treatments.

October 30th 2014

EMA Grants Orphan Status to Kiadis Pharma's Immuno-oncology Molecule

The European Medicines Agency granted an orphan status to ATIR, a T-cell immunotherapy-based medicinal product being developed to treat blood cancers.

October 29th 2014

Prostate Cancer Screening Remains Highly Debated

While the USPSTF recommended against screening for prostate cancer, citing the high rate of false positives, complications from biopsy, and side-effects of aggressive treatment for a sometimes slowly-progressing disease, several medical organizations disagree.

October 28th 2014

Nanodevice to Help Titrate and Individualize Chemotherapy

A miniature device can measure a patient's blood for methotrexate, a commonly used but potentially toxic cancer drug.

October 28th 2014

From Diagnostics to Cancer Drug Costs, Nothing's Off Limits at AJMCLive's Patient-Centered Oncology Care

The toughest topics in cancer care will be on tap November 13-14, 2014, in Baltimore, Maryland, when AJMCLive presents Patient-Centered Oncology Care. If you've followed the discussion among pharmaceutical leaders, oncologists, and payers over access to care, you'll want to join stakeholders to discuss how to ensure patients get what they need while controlling costs.

October 28th 2014

Friction Between Health Plans, Pharma Grows Over Specialty Drugs

Mary K. Caffrey

The war of words between managed care and pharmaceutical manufacturers, which began when Gilead set the price for its drug to treat the hepatitis C virus (HCV), has taken off in October with the reclassification of a trio of cancer drugs from Genentech. Growth in the "specialty pharma" sector, where prices are rising much faster than drug prices generally, has drawn concern from payers and the umbrella group that represents them, while the trade group that represents drugmakers is pushing back against critics, saying that it faces challenges in bringing life-saving therapies to market.

October 27th 2014

Breakthrough Designation for Merck's Keytruda in NSCLC

Recently approved as second-line treatment of metastatic melanoma, following resistance to ipilimumab, the FDA has now designated Keytruda as breakthrough therapy to treat EGFR-mutation and ALK-rearrangement negative NSCLC patients who have pr0gressed following platinum-based therapy.

October 27th 2014

Breast Cancer Risk Increased Following Chest Irradiation in Children

Radiation exposure due to chest irradiation in women who had childhood Wilms tumor increased their susceptibility to developing breast cancer later in life.

October 27th 2014

Merck's Rapid Strides With Pembrolizumab

Surabhi Dangi-Garimella, PhD

Today, Merck announced that Keytruda has been granted breakthrough therapy designation for treating patients with epidermal growth factor receptor mutation-negative and anaplastic lymphoma kinase rearrangement-negative non-small cell lung cancer (NSCLC).

October 27th 2014

Scientists Identify a Novel Wnt Signaling Regulator in Colorectal and Endometrial Cancers

The gene mutation in RNF43, previously missed in The Cancer Genome Atlas study, was identified in 20% of colorectal and endometrial cancers.

October 26th 2014

Evidence Shows Improved OS With Delayed Radiation Following Glioblastoma Surgery

The UCSF study identified a window of 30 to 35 days post surgery, following surgery in patients with glioblastoma multiforme, when delayed radiation significantly improved OS and PFS.

October 26th 2014

Nanotechnology Can Aid Early Cancer Diagnosis

This novel fluorescent imaging technique uses shortwave IR, which has much better tissue penetration than near-IR currently used in imaging.

October 26th 2014

In the Literature: A Speech Gene Prevents Breast Cancer Metastasis

The study, published in Cell Stem Cell, identified a microRNA-mediated inhibitory pathway that repressed expression of the speech and language gene FOXP2, promoting metastases of breast cancer cells to distant sites.

October 25th 2014

Quality of Care Takes Precedence for Breast Cancer Patients in New Jersey

Horizon BCBS partners with RCCA to improve quality of care for breast cancer patients by evaluating their molecular subtype before administering treatment.

October 25th 2014

MIT Scientists Develop A Rapid Modeling Technique for Cancer Gene Mutations

The group, led by Koch Institute director Tyler Jacks, used CRISPR to generate mutant genes that were then packaged into enteroviruses that were used to infect target organs in mice. This is a much faster process than the traditional method that need crossing genetically-engineered mice.

October 24th 2014

VeriStrat Proteomic Test Approved by NCCN for Inclusion in NSCLC Treatment

October 23rd 2014

Collaborative Model Succeeds in Reducing Cancer Patient Readmissions

Oncologists and palliative care specialists at Duke University Hospital worked together in patient care, resulting in a 23% reduction in patient readmission within a week of discharge.

October 22nd 2014

Everolimus Under FDA Scrutiny For Potential Risk

Everolimus has been added to FDA's Adverse Event Reporting System due to a possible risk of hypertension.

October 21st 2014

Fast Track for Taiho Oncology's mCRC Molecule

Taiho Oncology, Inc, announced that the FDA granted Fast Track designation for an oral combination anticancer drug under investigation for the treatment of refractory metastatic colorectal cancer.

October 21st 2014

In the Literature: New Lead in Treating ALL

The paper, published in Nature, has identified a "switch" that can be inhibited to restrict tumor growth.

October 20th 2014

A SNP That Affords Protection From Breast Cancer Identified

The study, published in the journal Nature Communications, identified the single nucleotide polymorphism near the coding region of the estrogen receptor ESR1 among Latina women.

October 20th 2014

Including Panobinostat Improves PFS in Multiple Myeloma

Including panobinostat in a regimen that included bortezomib and dexamethasone improved median PFS to 11.9 months as compared with 8.08 months in the control arm.

October 19th 2014

Success of Medicare's Prescription-Subsidy Program Among Low-Income Women

A study presented at ASCO's Quality Care Symposium in Boston found increased medication adherence to prevent breast cancer recurrence in those availing of the subsidies.

October 18th 2014

CMS Issues Draft Coverage Decision For Prostate Cancer Test by GenomeDX

The Decipher test is intended for use in men who have undergone radical prostatectomy and are at a high risk of disease recurrence.

October 18th 2014

Janssen's Imbruvica Approved by the European Commission

Imbruvica (ibrutinib) is a first-in-class BTK inhibitor with potential for treating blood cancer, indicated for use in MCL and CLL patients.

October 18th 2014

Exact Sciences' Cologuard Receives CMS National Coverage

The non-invasive nature of the test makes it a very attractive alternative to the uncomfortable colonoscopy used to detect colorectal cancer. In a New England Journal of Medicine study of 10,000 patients, the test identified 92% of colorectal cancers in average-risk patients and 42% of polyps.

...

147 148 149 150 151 152 153 154 155

...

184 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions